Start Taking Action for Tuberculosis in Kids

NCT ID: NCT07248423

Last Updated: 2025-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

7920 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-01

Study Completion Date

2027-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Start4Kids: Evaluating the performance, feasibility, acceptability and cost effectiveness of computer-aided detection (CAD) of chest X-ray (CXR) and concurrent testing using novel diagnostics and non-sputum specimens for childhood tuberculosis (TB) in Bangladesh, Cameroon, Kenya and Viet Nam.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each year an estimated 1.25 million children and adolescents under 15 years old become sick due to tuberculosis (TB). Despite TB being preventable and curable, in 2023, approximately 191 000 children died from the disease (Global Tuberculosis Report 2024). While treatment is both effective and tolerable, case detection continues to challenge many national TB programmes (NTPs), particularly in children under 5 years old. Less than half of children and young adolescents with TB are diagnosed and notified each year. Diagnostic gaps The reasons for this large gap in case detection are multiple. In children, obtaining sputum is particularly challenging as they rarely expectorate, and invasive collection procedures such as gastric aspiration or induced sputum are often required. This limits the feasibility of routine bacteriological testing, especially within lower levels of care. When sputum can be obtained, specimen collection, particularly in younger children, requires trained and experienced staff. Bacteriological confirmation is less frequent due to the paucibacillary nature of disease in children and the resultant reduction in sensitivity when using available diagnostic tests. To address these limitations, research studies and programmes often apply the NIH clinical case definition as a reference standard, recognising the challenges of achieving microbiological confirmation in this age group. However, this approach also has limitations, as chest X-ray, a key component of the definition, has inherent limitations in diagnostic accuracy, even when interpreted under standardised conditions by multiple experts and particularly so in small children. Further, clinical syndromes are often non-specific and can be rapidly progressive, resulting in frequent misdiagnosis and associated early mortality.

To overcome some of these barriers, health systems often require referral of children with signs, symptoms, or screening investigations consistent with TB ("presumptive TB") to secondary or tertiary health centres so that expert staff can be consulted, and relevant specimens, or further specimens, taken. This may result in additional cost for both the child and their family and the health system, cause further delays in diagnosis and treatment initiation, and may ultimately result in greater morbidity and mortality.

To reduce the case detection gap and to avoid diagnostic delays, policymakers and programme implementers have promoted child and adolescent TB assessment at primary healthcare (PHC) or child health centres, often through integration into existing child services diagnosing similar conditions. While child TB case notifications prior to the COVID-19 pandemic had been increasing, they declined sharply between 2019 and 2020 due to COVID. Childhood notifications recovered more slowly compared to adults in 2021, and efforts continue to be hampered by limited PHC staff expertise, poor access to diagnostic tests including chest X-ray, and a lack of dedicated time for over-burdened health care staff.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TB - Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic

Diagnostic Test - all participants

Group Type OTHER

Xpert MTB/RIF Ultra

Intervention Type DIAGNOSTIC_TEST

automated molecular test

Truenat, MTB

Intervention Type DIAGNOSTIC_TEST

Micro-Polymerase Chain Reaction (PCR) diagnostic test

Truenat MTB Plus

Intervention Type DIAGNOSTIC_TEST

Micro-Polymerase Chain Reaction (PCR) diagnostic test

TB LAMP

Intervention Type DIAGNOSTIC_TEST

manual molecular test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xpert MTB/RIF Ultra

automated molecular test

Intervention Type DIAGNOSTIC_TEST

Truenat, MTB

Micro-Polymerase Chain Reaction (PCR) diagnostic test

Intervention Type DIAGNOSTIC_TEST

Truenat MTB Plus

Micro-Polymerase Chain Reaction (PCR) diagnostic test

Intervention Type DIAGNOSTIC_TEST

TB LAMP

manual molecular test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 14 and below on the day of assessment
2. Fulfils the criteria of presumptive TB according to the definition 10.1 of the protocol, or TB associated risk factors according to the definition 10.2. of the protocol
3. Diagnosed with TB disease

Exclusion Criteria

1. On treatment for TB disease at the time of evaluation
2. Parent or guardian does not allow the child to participate in the study or declines to sign the ICF.
3. The child does not wish to participate in the study or declines to sign the Assent Form (where applicable)
Minimum Eligible Age

0 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre for Control of Chronic Disease (CCCD),icddr,b

UNKNOWN

Sponsor Role collaborator

Comité National d'Ethique pour la Recherche en Santé Humaine

UNKNOWN

Sponsor Role collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

Sponsor Role collaborator

National Lung Hospital, Vietnam

UNKNOWN

Sponsor Role collaborator

Liverpool School of Tropical Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microneedles for Diagnosis of LTBI
NCT04552015 TERMINATED NA